H1 FY26 Results Presentation

• Pascal orders for FebriDx growing significantly, with a decision by US FDA on CLIA waiver anticipated
• Onboarding new customers on the Pascal platform, with best-in-class Pascal performance increasingly recognised and valued in the market
• Continued organic growth in the HIV business, with more than A$1.6m in orders received during Q3 FY26

Atomo Diagnostics reported a 6% increase in revenue to $2.18m for H1 FY26, with underlying EBITDA loss effectively halved to ~$1.0 million. The company saw strong growth in its Pascal OEM business, with orders for FebriDx increasing significantly and the company onboarding new customers. The HIV self-test segment also continued to grow organically, with more than A$1.6m in orders received during Q3 FY26. Atomo made progress on new product development, securing an exclusive license to commercialize a novel liver function test which is already under evaluation by a potential multinational pharma partner. The company's Active Syphilis test also demonstrated best-in-class diagnostic specificity, with preliminary engagement with clinicians, regulators and government encouraging. Atomo remains in a strong financial position, with a cash balance of $3.51m as of 31 December 2025 and no debt.

Atomo anticipates a significant increase in demand from FebriDx in the coming years, noting that Lumos anticipates a decision from US FDA on FebriDx CLIA waiver during Q3 FY26. Lumos has previously disclosed significant contract demand for FebriDx, subject to securing CLIA waiver.

Atomo sees two key drivers of long-term growth in HIV: increasing demand in Retail markets post COVID and emerging Public Health Procurement for Infectious Disease Self-Testing. The company is also focused on expanding its Pascal OEM business, bringing new Atomo finished tests to market, and increasing cost efficiencies to achieve profitability.